COMMUNIQUÉS West-GlobeNewswire

-
Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
30/11/2018 -
La FDA américaine approuve le test de mutation LeukoStrat CDx FLT3 d’Invivoscribe comme CDx et le médicament XOSPATA (fumarate de gilteritinib) d’Astellas pour le traitement des patients atteints de LMA aux États-Unis
30/11/2018 -
Aino Health AB (publ): Aino Health and Finla in joint client project
30/11/2018 -
Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema
30/11/2018 -
Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018
30/11/2018 -
Eckert & Ziegler BEBIG to restructure its implant business
30/11/2018 -
Eckert & Ziegler BEBIG réorganise son secteur des implants
30/11/2018 -
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today
30/11/2018 -
INNATE PHARMA : Publication of monalizumab research in the prestigious "Cell" journal
30/11/2018 -
Innate Pharma: Publication, dans la prestigieuse revue scientifique « Cell », de travaux de recherche sur monalizumab
30/11/2018 -
Lexington Announces Q3 2018 Financial Results and Non-Brokered Private Placement
30/11/2018 -
Oncology Venture enters into financing agreement
30/11/2018 -
Update -- US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
30/11/2018 -
EDAP TMS SA : EDAP Announces Expiration of Second and Final Tranche of Outstanding Warrants
29/11/2018 -
PhaseBio Reports Third Quarter 2018 Financial and Business Results
29/11/2018 -
MPX Reports Financial Results for Its Fiscal Second Quarter of 2019
29/11/2018 -
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
29/11/2018 -
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
29/11/2018 -
ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
29/11/2018
Pages